KLF9 and non-small cell lung carcinoma: Compared with the control group, the plasma and exosomal miR‐660‐5p of NSCLC patients were significantly increased, and miR‐660‐5p may inhibit the proliferation, migration, and invasion of NSCLC by targeting KLF9, providing a potential therapeutic target for NSCLC.15